Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2026)

Crinetics Pharmaceuticals has reported Share-based Compensation for 10 years, with the latest figure at $29.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 44.94% year-over-year to $29.7 million; the trailing twelve-month figure through Mar 2026 stood at $100.2 million (up 31.17% YoY), and the FY2025 full-year result was $91.0 million, up 31.18% from the prior year.
• Share-based Compensation for Q1 2026 stood at $29.7 million, up from $21.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $29.7 million in Q1 2026, with the low at $5.8 million in Q1 2022.
• Average Share-based Compensation over 5 years is $15.3 million, with a median of $13.5 million recorded in 2024.
• Year-over-year, Share-based Compensation soared 86.14% in 2024 and increased 15.26% in 2025.
• Tracing CRNX's Share-based Compensation over 5 years: stood at $7.9 million in 2022, then soared by 46.16% to $11.6 million in 2023, then surged by 62.22% to $18.8 million in 2024, then climbed by 15.26% to $21.7 million in 2025, then jumped by 36.65% to $29.7 million in 2026.
• The last three Share-based Compensation figures came in at $29.7 million (Q1 2026), $21.7 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.

Peer Comparison